Decoding adverse drug reactions in respiratory care: a prospective predictive and severity-based analysis at a tertiary care hospital in India

Submitted: March 10, 2025
Accepted: April 3, 2025
Published: May 15, 2025
Abstract Views: 56
PDF_EARLY VIEW: 21
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Adverse drug reactions (ADRs) are a major concern in healthcare, including morbidity, longer hospitalization, and increased healthcare expenses. Despite the necessity of ADR monitoring, reporting is poor, particularly in developing countries such as India. This study assessed the severity, predictability, and causality of ADRs in a tertiary care hospital's respiratory department. A prospective observational study was conducted at KLE’s Dr. Prabhakar Kore Hospital, Belagavi, Karnataka, from September 2023 to January 2025. Patients aged 45 years and above with chronic respiratory conditions were included. ADRs were assessed using validated scales, including the World Health Organization-Uppsala Monitoring Centre Scale, Modified Hartwig and Siegel Scale, and Predictability Assessment. Descriptive statistics were applied to analyze ADR patterns. Among the 107 patients enrolled, 63.5% were elderly and 59.8% were female. Mild ADRs accounted for 60.7% of cases, while serious responses were reported in 3.7%. Predictability analysis revealed that 77.5% of ADRs were foreseeable. Causality assessment revealed ADRs as probable (51.4%), possible (37.3%), and certain (10.2%). Drug withdrawal was the most popular intervention (55.1%). The most commonly reported ADRs were gastrointestinal disorders (33.6%), followed by respiratory (18.6%) and cardiovascular disorders (16.8%). The study highlighted the need for improved pharmacovigilance programs to reduce ADR-related hazards in respiratory patients. Improving ADR reporting methods and predictive assessments can enhance patient safety and maximize therapeutic outcomes.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Sahu RK, Yadav R, Prasad P, et al. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus 2014;3:695. DOI: https://doi.org/10.1186/2193-1801-3-695
Sriram S, Ghasemi A, Ramasamy R, et al. Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J Res Med Sci 2011;16:16-25.
Khan A, Adil MS, Nematullah K, et al. Causality assessment of adverse drug reaction in pulmonology department of a tertiary care hospital. J Basic Clin Pharm 2015;6:84-8. DOI: https://doi.org/10.4103/0976-0105.160744
Gershnabel Milk D, Lam KK, Han JK. Postmarketing analysis of eosinophilic adverse reactions in the use of biologic therapies for type 2 inflammatory conditions. Am J Rhinol Allergy 2025;39:38-48. DOI: https://doi.org/10.1177/19458924241280757
Zou SP, Yang HY, Ouyang M, et al. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 2024;23:353-62. DOI: https://doi.org/10.1080/14740338.2023.2251382
Li W, Tang SC, Jin L. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments. BMC Pulm Med 2024;24:70. DOI: https://doi.org/10.1186/s12890-024-02885-2
Baniasadi S, Fahimi F. Adverse drug reactions in a pulmonary teaching hospital: incidence, pattern, seriousness, and preventability. Curr Drug Saf 2011;6:230-6. DOI: https://doi.org/10.2174/157488611798280942
Giardina C, Cutroneo PM, Mocciaro E, et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (facilitation of reporting in hospital ward) study. Front Pharmacol 2018;9:350. DOI: https://doi.org/10.3389/fphar.2018.00350
Singh A, Prasad R, Balasubramanian V, et al. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clin Epidemiol Glob Health 2015;3:S80-90. DOI: https://doi.org/10.1016/j.cegh.2015.10.005
Jennings E, Gallagher P, O'Mahony D. Detection and prevention of adverse drug reactions in multi-morbid older patients. Age Ageing 2019;48:10-3. DOI: https://doi.org/10.1093/ageing/afy157

Ethics Approval

The study protocol was approved by the KLE COP Ethics Committee Belagavi (reference number KLECOPBGMEC/D005-2023).

How to Cite

Gaonkar, Vaishnavi V., Vinay V. Shanbhag, Mandati Santhosh Reddy, and M.S. Ganachari. 2025. “Decoding Adverse Drug Reactions in Respiratory Care: A Prospective Predictive and Severity-Based Analysis at a Tertiary Care Hospital in India”. Monaldi Archives for Chest Disease, May. https://doi.org/10.4081/monaldi.2025.3464.